MA44054A - Plateforme d'anticorps bispécifique - Google Patents

Plateforme d'anticorps bispécifique

Info

Publication number
MA44054A
MA44054A MA044054A MA44054A MA44054A MA 44054 A MA44054 A MA 44054A MA 044054 A MA044054 A MA 044054A MA 44054 A MA44054 A MA 44054A MA 44054 A MA44054 A MA 44054A
Authority
MA
Morocco
Prior art keywords
bispecific antibody
antibody platform
platform
bispecific
antibody
Prior art date
Application number
MA044054A
Other languages
English (en)
French (fr)
Inventor
Martin Preyer
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA44054A publication Critical patent/MA44054A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA044054A 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique MA44054A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18

Publications (1)

Publication Number Publication Date
MA44054A true MA44054A (fr) 2018-10-24

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044054A MA44054A (fr) 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique

Country Status (9)

Country Link
US (1) US11447575B2 (2)
EP (1) EP3389710A1 (2)
JP (2) JP7138046B2 (2)
KR (1) KR20180100136A (2)
CN (1) CN108601830B (2)
AU (1) AU2016370821A1 (2)
CA (1) CA3008840A1 (2)
MA (1) MA44054A (2)
WO (1) WO2017106462A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901557XA (en) * 2016-08-26 2019-03-28 Sanofi Sa Multispecific antibodies facilitating selective light chain pairing
EP3661555B1 (en) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020159918A2 (en) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20220227827A1 (en) * 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
CN114302893B (zh) * 2019-08-15 2025-01-28 瑞泽恩制药公司 用于细胞靶向的多特异性抗原结合分子及其用途
KR20220050166A (ko) * 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 Igm 글리코변이체
JP2022550316A (ja) * 2019-09-25 2022-12-01 ウニヴェルズィテート シュトゥットガルト 修飾ｅｈｄ２ドメインを含む結合モジュール
CA3164979A1 (en) * 2020-01-09 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. New polypeptide complex
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
IL301926A (en) * 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
CA3219388A1 (en) * 2021-05-14 2022-11-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
KR20250075665A (ko) * 2022-09-28 2025-05-28 드렌 바이오, 인크. 다중특이적 항체 및 이의 사용 방법
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
CN121148519B (zh) * 2025-11-18 2026-02-13 西北农林科技大学 基于计算模拟辅助的双特异性抗体分子设计与优化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5768147B2 (ja) * 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2855531A1 (en) * 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
SG11201901557XA (en) * 2016-08-26 2019-03-28 Sanofi Sa Multispecific antibodies facilitating selective light chain pairing
CA3120800A1 (en) * 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager

Also Published As

Publication number Publication date
JP2019502694A (ja) 2019-01-31
US11447575B2 (en) 2022-09-20
EP3389710A1 (en) 2018-10-24
KR20180100136A (ko) 2018-09-07
CA3008840A1 (en) 2017-06-22
JP2021121642A (ja) 2021-08-26
WO2017106462A1 (en) 2017-06-22
CN108601830B (zh) 2023-02-03
JP7138046B2 (ja) 2022-09-15
US20190048098A1 (en) 2019-02-14
AU2016370821A1 (en) 2018-07-12
CN108601830A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52742A (fr) Anticorps bispécifiques dll3-cd3
FR25C1022I2 (fr) Anticorps anti-pd-1
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
EP3507307A4 (en) BISPECIFIC ANTIBODIES
EP3498840A4 (en) ANTI-LAG-3 ANTIBODY
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (en) ANTI-TIGITE ANTIBODY
EP3423089A4 (en) ANTI-Tigit ANTIBODY
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (en) ANTI-Tigit ANTIBODY
EP3334824A4 (en) PD-1 ANTIBODY
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
EP3359573A4 (en) MARKING OF ANTIBODIES
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3307321A4 (en) MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
EP3492591A4 (en) ANTI-B7-H4 ANTIBODIES
EP3383915A4 (en) PD-1 ANTIBODY
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
EP3526247A4 (en) Anti-il1-rap antibodies